Navigation Links
ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board
Date:2/14/2008

on the company's exclusive collection of microorganisms and fungi isolated from extreme environments. ZyGEM is also developing several new and complementary technology platforms.

"I am delighted to join the ZyGEM team at such an exciting time in the company's development," said Dr. Ahn. "I look forward to supporting ZyGEM's efforts as it expands its enzyme-based solutions and other novel technologies into new market segments that will bring the benefits of its innovative approaches more directly to physicians and patients."

Dr. Ahn is Professor and Chair, Science & Technology Entrepreneurship with a joint appointment from the faculties of Commerce & Administration and Science at Victoria University of Wellington. Prior to joining the university, Dr. Ahn was founder, President, and Chief Executive Officer of Hana Biosciences. Prior to Hana, he served as Vice President, Hematology and corporate officer at Genentech. Previously, he held a series of positions of increasing responsibility at Amgen and Bristol-Myers Squibb. Dr. Ahn also serves on the Boards of Directors of RXi Pharmaceuticals and Access Pharmaceuticals. He received B.A. and M.B.A. degrees from Chaminade University of Honolulu and holds a Ph.D. from the University of South Australia.

About ZyGEM

ZyGEM Corporation Limited is a rapidly growing biotechnology company with a range of innovative enzyme-based products and technologies based on the company's exclusive collection of microorganisms from extreme environments. ZyGEM's technology has significant competitive advantages over existing methods and has potential applications in a number of sizeable global markets. ZyGEM currently produces DNA extraction and detection products, molecular biology enzymes and individual enzymes and diagnostics, serving life sciences customers in basic research, forensics, clinical diagnostics and agriculture. ZyGEM has facilities in New Zealand and the U.S. For more information, visit

SOURCE ZyGEM Corp. Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Laureate Pharma Appoints Gary Swan as Vice President of Operations
2. Immtech Appoints Blythe Weigh as Strategic Advisor
3. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
4. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
5. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
6. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
7. Anesiva Appoints Daniel Janney to Board of Directors
8. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
9. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
10. Transgenomic Appoints David Pauluzzi to Board of Directors
11. China Pharma Appoints Three Independent Non-Executive Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Toronto, Canada (PRWEB) May 24, 2013 ... selective barriers, and uptake or efflux transporters at the ... may be related to unbound fractions in the tissue ... understanding of these disposition challenges is required to guide ... and to identify any species-dependent variables that may impact ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly ... and development, sales and marketing of premium branded ... that it is awarding exclusive Vestiage territories in ... Skin Illuminating Facial Care. Qualified applicants can request ... email to info(at)vestiageinc(dot)com and putting RELUMA in the ...
(Date:5/23/2013)... , May 24, 2013 ... angefertigt – Bei der englischen ... , 91 % der Teilnehmer einer groß angelegten ... 20 % laut GINA [*] -Definition [1] als ... Menschen mit Asthma generell einer von vier Denkweisen zugeordnet ...
(Date:5/23/2013)... May 23, 2013 Venaxis, Inc. (Nasdaq:   ... on obtaining FDA clearance and commercializing its rapid, protein ... pricing of an underwritten public offering of 10,000,000 shares ... 3,500,000 shares of its common stock at an exercise ... offering price of $1.25 per share and related warrant.  ...
Breaking Biology Technology:DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... SHANGHAI, Feb. 28, 2011 /PRNewswire-Asia-FirstCall/ -- ShengdaTech, Inc. ("ShengdaTech" ... leading manufacturer of nano-precipitated calcium carbonate ("NPCC") in China, ... and CEO, Ms. Anhui Guo, COO and acting CFO ... attend the Rodman & Renshaw Annual China Investment Conference ...
... announces a special edition of its Key ... Disease Day 2011 , an international event to raise awareness ... Dialogue spanned two continents and provided a platform ... caregivers and healthcare providers. (Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO) ...
... VILLAGE, Nev., Feb. 28, 2011 PDL BioPharma, Inc. ... it has entered into a definitive settlement agreement with ... settlement agreement, PDL agreed to dismiss its claims against ... includes Genentech, Inc. (Genentech) and F. Hoffmann-La Roche Ltd ...
Cached Biology Technology:ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai 2Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 2Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 3Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 4Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 5PDL Settles Litigation and Resolves Other Disputes 2
(Date:5/24/2013)... Frontiers, one of the world,s largest and fastest growing ... journal, Frontiers in Physics . , A broad ... will provide an open-science and interactive web platform ... rigorously peer-reviewed articles. , Frontiers, real-time and interactive ... range of article types. With an average of three ...
(Date:5/24/2013)... scientists have focused among other factors on drugs ... is the accumulation of A-beta that causes the known plaques ... formation of A-beta is APP. Alessia Soldano and Bassem Hassan ... APPL the fruit-fly version of APP in the ... Leuven): "We have discovered that APPL ensures that brain cells ...
(Date:5/23/2013)... year, carrying more than 284 million tons of cargo, transit ... in toll fees for the Panama Canal Authority. Each time ... water are used from Gatun Lake, which is also a ... the isthmus. , However, the advent of very large ... ships at sea, has demanded change. The Panama Canal is ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3A new strategy required in the search for Alzheimer's drugs? 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... are involved in activating and directing other immune cells, ... over-aggressive responses of the T cell population. , Researchers ... Teff cells in order to better shape the immune ... Memorial Sloan-Kettering Cancer Center, New York, demonstrated that an ...
... barrier against infection but skin cells themselves can mount an ... (AMPs). , As overt infection in the skin is a ... help fight infection, but play a role in preventing infection ... online on June 15 in advance of print publication in ...
... scientists have developed the first-ever genomic test to predict ... to live and which patients can avoid the toxic ... potential to save thousands of lives each year by ... it, said the test's developers at Duke's Institute for ...
Cached Biology News:First-ever genomic test predicts which lung cancer patients need chemotherapy to live 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 3First-ever genomic test predicts which lung cancer patients need chemotherapy to live 4
... Rabbit Tissue Arrays contain 60 rabbit tissue samples ... contains 4 unstained slides and 1 hematoxylin and ... slide contains 15 different tissues from 4 rabbit ... per slide. Each tissue sample (or core) is ...
A univariate (peak height or area) quantitative multi-component analysis package....
... represents a major advance in liquid dispensing ... of large robotic liquid handlers into the ... accurate volumes ranging from 10mL to 2mL ... advantages not yet found in other benchtop ...
... pyruvate, 50 mg/L streptomycin sulfate, 100 mg/L ... and magnesium chloride. The use of a ... is generally attributed to early workers in ... a solution of inorganic salts designed to ...
Biology Products: